SBIR/STTR Research Award
CLEARING OF TUMOR CELLS FROM HUMAN BONE MARROW CULTURES
Award amount
$49,584Program and phase
SBIR · Phase IAward year
1991Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Cellco Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
THE PURPOSE OF THE PRESENT PROTOCOL IS TO DEVELOP AN IN VITRO MEANS BY WHICH HUMAN BONE MARROW CAN BE CLEARED OF METASTATIC FOCI OF CARCINOMA. PRELIMINARY IN VITRO EXPERIMENTS PERFORMED WITH CELLMAXTM HOLLOW FIBER CELL CULTURE SYSTEMS DEMONSTRATED THAT 1) NORMAL HUMAN MARROW CAN BE GROWN TO PRODUCE PLURIPOTENT CELLS YIELDING ALL HEMATOPOIETIC CELL TYPES AND 2) HUMAN T LYMPHOCYTES CAN BE EXPANDED TO MASSIVE NUMBERS FOR CLINICAL THERAPY. ACTIVATED T CELLS DESTROY NEOPLASTIC CELLS BOTH IN VIVO AND IN VITRO. WE WILL CULTURE ALIQUOTS OF BONE MARROW FROM TEN PATIENTS, EACH CONTAINING METASTATIC NEUROBLASTOMA, BREAST OR PROSTATE CARCINOMA. THESE MARROWS WILL BE MAINTAINED WITHIN CONTINUOUSLY PERFUSED HOLLOW FIBER BIOREACTORS FOR 3 WEEKS DURING WHICH TIME, THE ENDOGENOUS T CELLS WILL BE ACTIVATED AND EXPANDED BY ADDITION OF RIL-2. CELLS WILL THEN BE HARVESTED FROM THE EXTRA-FIBER SPACE AND THE NUMBERS OF BOTH MALIGNANT CELLS AND COLONY-FORMING BONE MARROW STEM CELLS DETERMINED. PHENOTYPIC AND IN VITRO CYTOTOXICITY PROFILES WILL ALSO BE DETERMINED. SUCCESSFUL DEPLETION OF MALIGNANT CELLS WITH CONCOMITANT MAINTENANCE OF THE COLONY-FORMING CELLS WITHIN HARVESTED MARROW COULD ENABLE PATIENTS HAVING SUCH METASTIC MALIGNANCIES TO BE TREATED WITH MARROW-DESTROYING DOSES OF CHEMOTHERAPY AND RADIATION THERAPY AND THEN BE RESCUED BY RE-INFUSION AND ENGRAFTMENT OF THEIR OWN MARROW.
Technology keywords
Not reported